Drug Trial Radar · NCT07399704
A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease
Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Feb 4, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Azafaros B.V.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label study aims to gather long-term safety, tolerability, PK, biomarker, and clinical efficacy data relating to daily administration of Nizubaglustat in participants previously enrolled in the Phase 2 RAINBOW study (Cohort 1). In addition, the study aims to assess safety, clinical, and biochemical impact of transitioning NPC disease patients to Nizubaglustat after prior treatment with stable, full-dose Miglustat (Cohort 2).
Conditions
- GM2 Gangliosidosis
- Niemann-Pick Type C Disease
Interventions
AZ-3102Drug
Daily oral intake of AZ-3102 dispersible tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 4 years
- Change from baseline in electrocardiogram (ECG)Time frame: Through study completion, an average of 4 years
- Change from baseline in seizuresTime frame: Through study completion, an average of 4 years
- Change from baseline in seizuresTime frame: Through study completion, an average of 4 years
- Maximum observed plasma concentration (Cmax)Time frame: Baseline , Month 1 (Cohort 2 only) and Month 6
- Time to Cmax (Tmax)Time frame: Baseline, Month 1 (Cohort 2 only) and Month 6
- Concentration at trough (Ctrough)Time frame: Baseline, Month 1 (Cohort 2 only) and Month 6
- Area under the plasma concentration-time curve from the time of dosing (zero) to 24 hours post-doseTime frame: Baseline, Month 1 (Cohort 2 only) and Month 6
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira
Rio de Janeiro, Brazil
Associação Hospitalar de Prot à Infância Dr. Raul Carneiro
Água Verde, Curitiba, Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.